Stéphane Bancel defended his melanoma data and argued that rivals can’t easily copy the technology.

Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker’s experimental cancer treatment.

If it does turn again, the question is how much more the stock could lose on top of this drop: in past market-wide downturns, ...

Moderna stock is surging even after an analyst cited its 636% yearly gain as reason enough to step back, and the real ...

Fintel reports that on 27 October 2026, William Blair downgraded their outlook for Moderna (SWX:MRNA) from Outperform to ...

The drop is a sharp reversal of a massive 2026 stock rally fueled by optimism over its personalized cancer vaccine.

Moderna’s stock has taken a big hit that might signal the end of this year’s cancer vaccine-driven rally. It may not, however ...

Moderna (MRNA) stock falls as William Blair downgrades the biotech, citing valuation concerns after a trial win for its Merck ...

The results, which triggered Moderna’s stock to drop, are “really encouraging,” says Karen Knudsen, CEO of the Parker ...

Moderna Inc. Chief Executive Officer Stephane Bancel said he believes the personalized mRNA cancer vaccine his company is ...

Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding ...

So, right now, is Moderna a buy on the dip? It's important to keep in mind that the stock still has climbed more than 500% ...